Pinebridge Investments L.P. Has $12.58 Million Stock Holdings in Solventum Co. (NYSE:SOLV)

Pinebridge Investments L.P. lifted its holdings in Solventum Co. (NYSE:SOLV - Free Report) by 401.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 190,358 shares of the company's stock after purchasing an additional 152,429 shares during the period. Pinebridge Investments L.P. owned 0.11% of Solventum worth $12,575,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. J. Safra Sarasin Holding AG acquired a new position in shares of Solventum during the fourth quarter worth approximately $1,521,000. Tower Research Capital LLC TRC lifted its holdings in shares of Solventum by 71.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,731 shares of the company's stock worth $445,000 after buying an additional 2,804 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Solventum by 1.8% during the fourth quarter. MetLife Investment Management LLC now owns 36,583 shares of the company's stock worth $2,417,000 after buying an additional 652 shares during the last quarter. Norinchukin Bank The lifted its holdings in shares of Solventum by 10.4% during the fourth quarter. Norinchukin Bank The now owns 6,357 shares of the company's stock worth $420,000 after buying an additional 599 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Solventum during the fourth quarter worth approximately $633,000.

Solventum Price Performance

Shares of SOLV stock traded up $0.30 during trading hours on Tuesday, hitting $66.37. 197,635 shares of the company's stock were exchanged, compared to its average volume of 1,295,816. The stock's 50-day moving average is $72.42 and its 200-day moving average is $71.59. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a market cap of $11.48 billion and a price-to-earnings ratio of 24.14. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92.

Analysts Set New Price Targets

A number of brokerages have recently commented on SOLV. Mizuho upped their price target on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. Morgan Stanley upped their target price on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th. The Goldman Sachs Group upped their target price on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. Wells Fargo & Company upped their target price on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research note on Friday, February 28th. Finally, Bank of America upped their target price on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, Solventum currently has a consensus rating of "Hold" and an average target price of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.